Doctors Call Moderna-Merck Melanoma Vaccine Trial Results Meaningful

Image: TokenPost
The combination lowered the hazard of recurrence or death by 42% in a 1,137-patient trial, but an overall-survival benefit has not been established.
Read the full story on TokenPostBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.







